OmniSeq News

OmniSeq & LabCorp Launch OmniSeq Advance℠ Assay

New test combines both targeted therapy and immune-oncology biomarkers in a single test with 99% actionability, providing benefits for the treatment of patients and the development of new therapies.ASCO, CHICAGO, ILLINOIS – June 1, 2018 – OmniSeq® , a CAP accredited,...

read more

OmniSeq & LabCorp Launch Tumor-Only MSI NGS Assay

BUFFALO, NEW YORK – April 16, 2018 – OmniSeq®, a molecular diagnostics subsidiary of the Roswell Park Comprehensive Cancer Center, and LabCorp® (NYSE: LH), a leading global life sciences company, announced today the commercial launch of OmniSeq MSI NGS, a tumor-only,...

read more

Launch of Immune Report Card

BUFFALO, N.Y., June 14, 2017 (GLOBE NEWSWIRE) -- OmniSeq, an innovation of Roswell Park Cancer Institute, announced today the commercial launch of Immune Report Card SM, the first immune profiling test designed to help oncologists select the best mono and...

read more

Follow Us on Twitter

OmniSeq is grateful for the continued support and partnership with @LABCORP . Together, we aim to expand patient access to market leading NGS diagnostics throughout the country. #NGS #TargetedTherapy #Immunotherapy #Diagnostics

https://t.co/oxmcNHLWcK

It has been 1 year since the launch of MSI-NGS. OmniSeq allows for MSI testing without the need for matched normal tissue. Let us maximize testing for this important immune oncology biomarker. We identified many MSI-H patients who could not have been tested by PCR! #AACR19

Thank you Wired Magazine and Empire State Development for featuring OmniSeq as a Western New York success story! #ngs #immunotherapy

How One NY Company Is Changing Cancer Treatment

https://t.co/4LFS221n7r

With the rapid growth of OmniSeq Advance we thought it might be time to break out an oldie but a goodie!

In recognition of our 1000th OmniSeq Advance order we would like to thank all of our customers and clinical partners!! Special thanks to our partners at @LABCORP and Integrated Oncology #NGS #immunooncology #PDL1

Load More...